In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community ...

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.

Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations.

Tiago Biachi, MD, PhD, discusses the challenges of treating gastrointestinal (GI) cancers, particularly the limited effectiveness of immunotherapy for "cold tumors" and the need to make them more ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.

The VET PFAS Act could help older veterans with toxic exposure attain the medical treatment they need by expanding ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always ...